Vectura Group PLC (VEC) – Research Analysts’ Weekly Ratings Changes

Vectura Group PLC (LON: VEC) recently received a number of ratings updates from brokerages and research firms:

  • 11/16/2017 – Vectura Group PLC had its “overweight” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 11/15/2017 – Vectura Group PLC had its “hold” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 160 ($2.10) price target on the stock.
  • 11/10/2017 – Vectura Group PLC had its price target lowered by analysts at J P Morgan Chase & Co from GBX 180 ($2.37) to GBX 175 ($2.30). They now have an “overweight” rating on the stock.
  • 11/9/2017 – Vectura Group PLC had its “buy” rating reaffirmed by analysts at Shore Capital.
  • 11/9/2017 – Vectura Group PLC had its “hold” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 160 ($2.10) price target on the stock.
  • 11/9/2017 – Vectura Group PLC had its price target lowered by analysts at Numis Securities Ltd from GBX 205 ($2.70) to GBX 170 ($2.24). They now have a “buy” rating on the stock.
  • 11/9/2017 – Vectura Group PLC had its “buy” rating reaffirmed by analysts at Panmure Gordon. They now have a GBX 150 ($1.97) price target on the stock.
  • 10/31/2017 – Vectura Group PLC had its “hold” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 160 ($2.10) price target on the stock.
  • 10/5/2017 – Vectura Group PLC had its “buy” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 205 ($2.70) price target on the stock.

Vectura Group PLC (LON VEC) opened at GBX 91.50 ($1.20) on Tuesday. Vectura Group PLC has a fifty-two week low of GBX 86.50 ($1.14) and a fifty-two week high of GBX 166.97 ($2.20).

In related news, insider Bruno Angelici acquired 70,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was purchased at an average cost of GBX 99 ($1.30) per share, for a total transaction of £69,300 ($91,148.23). Also, insider Andrew Derodra acquired 82,000 shares of the business’s stock in a transaction on Thursday, September 7th. The shares were bought at an average price of GBX 90 ($1.18) per share, with a total value of £73,800 ($97,066.95). Insiders purchased a total of 152,456 shares of company stock valued at $14,354,880 over the last quarter.

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply